Impact of IL-6 rs1800795 and IL-17A rs2275913 gene polymorphisms on the COVID-19 prognosis and susceptibility in a sample of Iranian patients.

[1]  J. Ju,et al.  Altered distribution, activation and increased IL-17 production of mucosal-associated invariant T cells in patients with acute respiratory distress syndrome , 2022, Thorax.

[2]  Ahmed El-Mesery,et al.  Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study , 2022, Clinical Immunology.

[3]  S. Fouad,et al.  Toll-Like Receptor 4 Polymorphisms (896A/G and 1196C/T) as an Indicator of COVID-19 Severity in a Convenience Sample of Egyptian Patients , 2021, Journal of inflammation research.

[4]  Ying Sun,et al.  A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19 , 2021, mBio.

[5]  R. Scarpa,et al.  Interleukin-17A (IL-17A): A silent amplifier of COVID-19 , 2021, Biomedicine & Pharmacotherapy.

[6]  N. Hekim,et al.  Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID‐2019) in 23 countries , 2021, Journal of medical virology.

[7]  B. Kerget,et al.  Frequency of interleukin-6 rs1800795 (-174G/C) and rs1800797 (-597G/A) polymorphisms in COVID-19 patients in Turkey who develop macrophage activation syndrome. , 2021, Japanese journal of infectious diseases.

[8]  E. Barbosa-Stancioli,et al.  Will a little change do you good? A putative role of polymorphisms in COVID-19 , 2021, Immunology Letters.

[9]  C. Hunter,et al.  Is IL-6 a key cytokine target for therapy in COVID-19? , 2021, Nature Reviews Immunology.

[10]  K. Fatema,et al.  Common genetic variants and pathways in diabetes and associated complications and vulnerability of populations with different ethnic origins , 2021, Scientific Reports.

[11]  L. de Noronha,et al.  Lung Neutrophilic Recruitment and IL-8/IL-17A Tissue Expression in COVID-19 , 2021, Frontiers in Immunology.

[12]  P. Reddanna,et al.  Overview on the Discovery and Development of Anti-Inflammatory Drugs: Should the Focus Be on Synthesis or Degradation of PGE2? , 2021, Journal of inflammation research.

[13]  G. Soraya,et al.  Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia , 2020, Medicina Clínica (English Edition).

[14]  Y. Shoenfeld,et al.  SARS-CoV-2, the autoimmune virus , 2020, Autoimmunity Reviews.

[15]  H. Mansouritorghabeh,et al.  D-dimer level in COVID-19 infection: a systematic review , 2020, Expert review of hematology.

[16]  R. Attou,et al.  Inhibiting IL-6 in COVID-19: we are not sure , 2020, Critical Care.

[17]  Reza Zolfaghari Emameh,et al.  Expansion of Single Cell Transcriptomics Data of SARS-CoV Infection in Human Bronchial Epithelial Cells to COVID-19 , 2020, Biological Procedures Online.

[18]  S. Rehman,et al.  Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review , 2020, Journal of medical Internet research.

[19]  Zhenghao Xu,et al.  Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies , 2020, Frontiers in Immunology.

[20]  M. Šitum,et al.  Potential role of IL‐17 blocking agents in the treatment of severe COVID‐19? , 2020, British journal of clinical pharmacology.

[21]  S. Bharadwaj,et al.  Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans , 2020, Journal of biomolecular structure & dynamics.

[22]  I. Adini,et al.  Racial disparity in Covid-19 mortality rates - A plausible explanation , 2020, Clinical Immunology.

[23]  Zhenyu Li,et al.  The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019 , 2020, EMBO molecular medicine.

[24]  A. Harky,et al.  The role of biomarkers in diagnosis of COVID-19 – A systematic review , 2020, Life Sciences.

[25]  A. Selva-O'Callaghan,et al.  Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review , 2020, Autoimmunity Reviews.

[26]  Thomas Henry,et al.  Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions , 2020, Autoimmunity Reviews.

[27]  A. Iagnocco,et al.  Cytokine storm syndrome in severe COVID-19 , 2020, Autoimmunity Reviews.

[28]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[29]  G. Fabbrocini,et al.  May IL-17 have a role in COVID-19 infection? , 2020, Medical Hypotheses.

[30]  Zhe Zhu,et al.  Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 , 2020, International Journal of Infectious Diseases.

[31]  T. Hirano,et al.  COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome , 2020, Immunity.

[32]  Stefano Volpi,et al.  On the Alert for Cytokine Storm: Immunopathology in COVID‐19 , 2020, Arthritis & rheumatology.

[33]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[34]  Qiurong Ruan,et al.  Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[35]  Centers for Disease Control and Prevention CDC COVID-19 Response Team.  Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[36]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[37]  T. Palaga,et al.  Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. , 2020, Asian Pacific journal of allergy and immunology.

[38]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[39]  A. Masotti,et al.  Evidences from a Systematic Review and Meta-Analysis Unveil the Role of MiRNA Polymorphisms in the Predisposition to Female Neoplasms , 2019, International journal of molecular sciences.

[40]  P. Mehrbod,et al.  Association of polymorphisms in inflammatory cytokines encoding genes with severe cases of influenza A/H1N1 and B in an Iranian population , 2019, Virology Journal.

[41]  A. Masotti,et al.  Association of mir-196a-2 rs11614913 and mir-149 rs2292832 Polymorphisms With Risk of Cancer: An Updated Meta-Analysis , 2019, Front. Genet..

[42]  A. Masotti,et al.  miRNA Polymorphisms and Risk of Cardio-Cerebrovascular Diseases: A Systematic Review and Meta-Analysis , 2019, International journal of molecular sciences.

[43]  Yvette N. Lamb,et al.  Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis , 2018, Drugs.

[44]  J. Li,et al.  Association between interleukin-17 genetic polymorphisms and tuberculosis susceptibility: an updated meta-analysis. , 2017, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[45]  M. Sheppard,et al.  Tocilizumab (Actemra) , 2017, Human vaccines & immunotherapeutics.

[46]  S. Rose-John,et al.  The role of IL-6 in host defence against infections: immunobiology and clinical implications , 2017, Nature Reviews Rheumatology.

[47]  I. Becker,et al.  Th17 cells and neutrophils: Close collaborators in chronic Leishmania mexicana infections leading to disease severity , 2017, Parasite immunology.

[48]  G. A. D. da Silva,et al.  The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia , 2016, BMC Pulmonary Medicine.

[49]  O. Polašek,et al.  The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia , 2016, PeerJ.

[50]  P. G. Choe,et al.  Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection , 2016, Journal of Korean medical science.

[51]  Ming Li,et al.  Association Analysis of Interleukin-17 Gene Polymorphisms with the Risk Susceptibility to Tuberculosis , 2016, Lung.

[52]  Lisa E. Gralinski,et al.  Molecular pathology of emerging coronavirus infections , 2014, The Journal of pathology.

[53]  Toshio Tanaka,et al.  IL-6 in inflammation, immunity, and disease. , 2014, Cold Spring Harbor perspectives in biology.

[54]  A. Glabinski,et al.  Interactions between Neutrophils, Th17 Cells, and Chemokines during the Initiation of Experimental Model of Multiple Sclerosis , 2014, Mediators of inflammation.

[55]  F. Rodríguez de Castro,et al.  Variants at the promoter of the interleukin-6 gene are associated with severity and outcome of pneumococcal community-acquired pneumonia , 2012, Intensive Care Medicine.

[56]  F. D’Acquisto,et al.  Interleukin 17 sustains rather than induces inflammation. , 2009, Biochemical pharmacology.

[57]  Saremi Mohammad Ali,et al.  Rapid genomic DNA extraction (RGDE) , 2008 .

[58]  D. Dash,et al.  Polymorphisms in the IL6 gene in Asian Indian families with premature coronary artery disease – The Indian Atherosclerosis Research Study , 2008, Thrombosis and Haemostasis.

[59]  Michael J. Rausch,et al.  Effect of the interleukin‐6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients , 2007, Hepatology.

[60]  M. Kawaguchi,et al.  Role of interleukin‐17F in chronic inflammatory and allergic lung disease , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[61]  M. Savage,et al.  Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Holle,et al.  Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[63]  J. Goedert,et al.  Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. , 2003, Gastroenterology.

[64]  C. Schneeberger,et al.  Analysis of an lnterleukin-6 Gene Promoter Polymorphism in Women With Endometriosis By Pyrosequencing , 2003, The Journal of the Society for Gynecologic Investigation: JSGI.

[65]  S. Steinberg,et al.  An IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. , 2000, Blood.

[66]  F. Green,et al.  Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation* , 2000, The Journal of Biological Chemistry.

[67]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[68]  J. Banchereau,et al.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines , 1996, The Journal of experimental medicine.

[69]  F. Stentz,et al.  Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS : plasma IL-1β and IL-6 levels are consistent and efficient predictors of outcome over time , 1995 .

[70]  Shiguo Liu,et al.  Polymorphisms in the IL-17 Gene (rs2275913 and rs763780) Are Associated with Hepatitis B Virus Infection in the Han Chinese Population. , 2017, Genetic testing and molecular biomarkers.

[71]  M. Pirisi,et al.  Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C , 2010, Immunogenetics.

[72]  K. Ley,et al.  IL-17A-producing neutrophil-regulatory Tn lymphocytes , 2006, Immunologic research.